⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12191016 | 0.74 | — | — | |
| SCHEMBL1275873 | 0.74 | — | — | |
| SCHEMBL5266758 | 0.72 | — | — | |
| SCHEMBL2194987 | 0.72 | — | — | |
| SCHEMBL10731186 | 0.72 | — | — | |
| SCHEMBL128608 | 0.69 | — | — | |
| SCHEMBL27938913 | 0.69 | — | — | |
| SCHEMBL4951114 | 0.69 | — | — | |
| SCHEMBL1126335 | 0.67 | — | — | |
| SCHEMBL698327 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2467373-B1 | A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN | CIPLA LTD (IN) | 2013-10-02 | — | — | EP | claimed |
| WO-2011021000-A2 | A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN | CIPLA LIMITED (IN) | 2011-02-24 | — | — | WO | claimed |
| JP-60229910-A | — | — | None | — | — | JP | disclosed |
| US-12220419-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240425520-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC (US) | 2024-12-26 | — | — | US | disclosed |
| US-20240180924-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2024-06-06 | — | — | US | disclosed |
| US-11993610-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-11903950-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2024-02-20 | — | — | US | disclosed |
| EP-3672976-B1 | BCL-2 INHIBITORS | GUANGZHOU LUPENG PHARMACEUTICAL COMPANY LTD (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | NEWAVE PHARMACEUTICAL INC. | 2023-09-21 | — | — | US | disclosed |
| CN-116621860-A | Bcl-2 inhibitors | 广州麓鹏制药有限公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2021066873-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-3672976-A1 | BCL-2 INHIBITORS | Newave Pharmaceutical Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20200197406-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2020-06-25 | — | — | US | disclosed |
| WO-2020041406-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020041405-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2019040573-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2011021000-A2 | A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN | CIPLA LIMITED (IN) | 2011-02-24 | — | — | WO | disclosed |
| US-4714481-A | Gas separation membrane | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1987-12-22 | — | — | US | disclosed |
| JP-S60229910-A | 1-ADAMANTHYLACETYLENE POLYMER | HIGASHIMURA TOSHINOBU | 1985-11-15 | — | — | JP | disclosed |